Tiletamine

DB11549

small molecule vet_approved

Deskripsi

This drug is a dissociative anesthetic agent that falls under the drug category of NMDA receptor antagonists. Tiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

Struktur Molekul 2D

Berat 223.33
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

813 Data
Buprenorphine Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Hydrocodone Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Magnesium sulfate The therapeutic efficacy of Tiletamine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Tiletamine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Mirtazapine Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Orphenadrine Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Pramipexole Tiletamine may increase the sedative activities of Pramipexole.
Ropinirole Tiletamine may increase the sedative activities of Ropinirole.
Rotigotine Tiletamine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Tiletamine.
Sodium oxybate The risk or severity of CNS depression can be increased when Sodium oxybate is combined with Tiletamine.
Suvorexant Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Thalidomide Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Tiletamine can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Tiletamine can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Tiletamine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Topotecan Tiletamine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Tiletamine.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Tiletamine.
Ethanol Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Tiletamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Fluvoxamine The risk or severity of adverse effects can be increased when Tiletamine is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Tiletamine is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Tiletamine is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Tiletamine is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Tiletamine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Tiletamine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Tiletamine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Tiletamine is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Tiletamine is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Tiletamine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Tiletamine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Tiletamine is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Tiletamine is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Tiletamine is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Tiletamine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Tiletamine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Tiletamine is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Tiletamine.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Tiletamine.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Tiletamine.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Tiletamine.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Tiletamine.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Tiletamine.
Cocaine The risk or severity of methemoglobinemia can be increased when Tiletamine is combined with Cocaine.
Quinidine The therapeutic efficacy of Tiletamine can be decreased when used in combination with Quinidine.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Tiletamine.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Tiletamine.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Tiletamine.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Tiletamine.
Dosulepin The risk or severity of CNS depression can be increased when Dosulepin is combined with Tiletamine.
Zopiclone The risk or severity of adverse effects can be increased when Tiletamine is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Tiletamine.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Tiletamine.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Tiletamine.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Tiletamine.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Tiletamine.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Tiletamine.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Tiletamine.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Tiletamine.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Tiletamine.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Tiletamine.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Tiletamine.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Tiletamine.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Tiletamine.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Tiletamine.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Tiletamine.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Tiletamine.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Tiletamine.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Tiletamine.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Tiletamine.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Tiletamine.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Tiletamine.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Tiletamine.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Tiletamine.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Tiletamine.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Tiletamine.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Tiletamine.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Tiletamine.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Tiletamine.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Tiletamine.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Tiletamine.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Tiletamine.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Tiletamine.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Tiletamine.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Tiletamine.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Tiletamine.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15053744
    Natalini CC, Alves SD, Guedes AG, Polydoro AS, Brondani JT, Bopp S: Epidural administration of tiletamine/zolazepam in horses. Vet Anaesth Analg. 2004 Apr;31(2):79-85.
  • PMID: 8430114
    Wilson RP, Zagon IS, Larach DR, Lang CM: Cardiovascular and respiratory effects of tiletamine-zolazepam. Pharmacol Biochem Behav. 1993 Jan;44(1):1-8.
  • PMID: 5115540
    Calderwood HW, Klide AM, Cohn BB, Soma LR: Cardiorespiratory effects of tiletamine in cats. Am J Vet Res. 1971 Oct;32(10):1511-5.
  • PMID: 2729719
    Hubbell JA, Bednarski RM, Muir WW: Xylazine and tiletamine-zolazepam anesthesia in horses. Am J Vet Res. 1989 May;50(5):737-42.
  • PMID: 14567228
    Cattet MR, Caulkett NA, Lunn NJ: Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine. J Wildl Dis. 2003 Jul;39(3):655-64.
  • PMID: 7986185
    Lin HC, Wallace SS, Tyler JW, Robbins RL, Thurmon JC, Wolfe DF: Comparison of tiletamine-zolazepam-ketamine and tiletamine-zolazepam-ketamine-xylazine anaesthesia in sheep. Aust Vet J. 1994 Aug;71(8):239-42.
  • PMID: 10884126
    Fernandez-Moran J, Palomeque J, Peinado VI: Medetomidine/tiletamine/zolazepam and xylazine/tiletamine/zolazepam combinations for immobilization of fallow deer (Cervus dama). J Zoo Wildl Med. 2000 Mar;31(1):62-4.
  • PMID: 10642872
    Caulkett NA, Cattet MR, Cantwell S, Cool N, Olsen W: Anesthesia of wood bison with medetomidine-zolazepam/tiletamine and xylazine-zolazepam/tiletamine combinations. Can Vet J. 2000 Jan;41(1):49-53.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul